Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Гормональная контрацепция без эстрогенов
Гормональная контрацепция без эстрогенов
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. World Contraceptive Use 2003 United Nations Department of Economic and Social Affairs Population Division.
2. Прилепская В.Н. Руководство по контрацепции. М .: МЕДпресс-информ, 2006.
3. Guillebaud J. Contraception. Your questions answered. 2nd edn. Edinburgh: Churchill Livingstone, 1993.
4. WHO, Medical eligibility criteria for contraceptive use, 2004.
5. Rosenberg L, Palmer JR, Sands MI et al. Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol 1997; 177: 707–15.
6. http://www.mzsrrf.ru/stat/44.html
7. LaVecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer. An update. Drug Safety 2001; 24: 741–54.
8. Fraser JS. Long-acting hormonal contraception: a comparison of key medical aspect. Oral presentation FIGO, 2006.
9. McCann MF, Potter LS. Progestin-only contraception: a comprehensive review. Contraception 1994; 50 (Suppl. 1): SI–198.
10. Darney PD. The androgenicity of progestins. Am J Med 1995; 98 (Suppl. 1 A): 104–1 OS.
11. Stone SC. Desogestrel. Clin Odstet Gynecol 1995; 38: 821–8.
12. Rice CF, Killick SR, Dieben T et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 Μg daily. Hum Reprod 1999; 14: 982–5.
13. Van Heusden AM, Fauser BJCM. Residual ovarian activity during oral steroid contraception. Hum Reprod Update 2002; 8: 345–58.
14. Schwartz JL, Creinin MD, Pymar HC, Reid L. Predicting risk of ovulation in new start oral contraceptive users. Obstet Gynecol 2002; 99: 177–82.
15. Pierson RA, Archer DA, Moreau M et al. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003; 80: 34–42.
16. Korver T, Klipping C, Heger-Mahn D et al. Maintenance of ovulation inhibition with the 75 mcg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-hour delays in tablet-intake. Contraception 2005; 7: 8–13.
17. Rice CF, Killick SR, Dieben T. The effect of desogestrel 75 μg and levonorgestrel 30 μg on the endometrium and bleeding patterns over one year. Br J Obstet Gynecol 1998; 105 (Suppl. 17): 114.
18. Obruca A, Korver T, Huber J et al. Ovarian function during and after treatment with new progestagen Org 30659. Fertil Steril 2001; 76: 108–15.
19. Collaborative Study Group on the Desogestrel-Containing Progestogen-only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and Safety of two progestagen-only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day. Eur J Contracept Reproduct Health Care 1998; 3: 169–78.
20. Miller A. Dysmenorrhoea. A systematic approach to management. J Ped Obstet Gynecol 1997; 6: 18–22.
21. Bjarnodotter RI, Geirsson RT, Gottfreosdottir H. An open non-randomised comparative study on the effects of desogestrel 0,075 mg/days vs an IUCD on lactation. Acta Obstet Gynecol Scand 1997; 76 (Suppl. 167): 53.
22. Godsland IF, Crook D. Pathogenesis of vascular disease in oral contraceptive users. Br J Cardiol 1996; 3: 204–8.
23. Wrinkler UH, Howie H, Buhler K et al. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel. Contraception 1998; 57: 385–92.
24. Carr BR, Ory H. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception 1997; 55: 267–72.
2. Прилепская В.Н. Руководство по контрацепции. М .: МЕДпресс-информ, 2006.
3. Guillebaud J. Contraception. Your questions answered. 2nd edn. Edinburgh: Churchill Livingstone, 1993.
4. WHO, Medical eligibility criteria for contraceptive use, 2004.
5. Rosenberg L, Palmer JR, Sands MI et al. Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol 1997; 177: 707–15.
6. http://www.mzsrrf.ru/stat/44.html
7. LaVecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer. An update. Drug Safety 2001; 24: 741–54.
8. Fraser JS. Long-acting hormonal contraception: a comparison of key medical aspect. Oral presentation FIGO, 2006.
9. McCann MF, Potter LS. Progestin-only contraception: a comprehensive review. Contraception 1994; 50 (Suppl. 1): SI–198.
10. Darney PD. The androgenicity of progestins. Am J Med 1995; 98 (Suppl. 1 A): 104–1 OS.
11. Stone SC. Desogestrel. Clin Odstet Gynecol 1995; 38: 821–8.
12. Rice CF, Killick SR, Dieben T et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 Μg daily. Hum Reprod 1999; 14: 982–5.
13. Van Heusden AM, Fauser BJCM. Residual ovarian activity during oral steroid contraception. Hum Reprod Update 2002; 8: 345–58.
14. Schwartz JL, Creinin MD, Pymar HC, Reid L. Predicting risk of ovulation in new start oral contraceptive users. Obstet Gynecol 2002; 99: 177–82.
15. Pierson RA, Archer DA, Moreau M et al. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003; 80: 34–42.
16. Korver T, Klipping C, Heger-Mahn D et al. Maintenance of ovulation inhibition with the 75 mcg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-hour delays in tablet-intake. Contraception 2005; 7: 8–13.
17. Rice CF, Killick SR, Dieben T. The effect of desogestrel 75 μg and levonorgestrel 30 μg on the endometrium and bleeding patterns over one year. Br J Obstet Gynecol 1998; 105 (Suppl. 17): 114.
18. Obruca A, Korver T, Huber J et al. Ovarian function during and after treatment with new progestagen Org 30659. Fertil Steril 2001; 76: 108–15.
19. Collaborative Study Group on the Desogestrel-Containing Progestogen-only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and Safety of two progestagen-only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day. Eur J Contracept Reproduct Health Care 1998; 3: 169–78.
20. Miller A. Dysmenorrhoea. A systematic approach to management. J Ped Obstet Gynecol 1997; 6: 18–22.
21. Bjarnodotter RI, Geirsson RT, Gottfreosdottir H. An open non-randomised comparative study on the effects of desogestrel 0,075 mg/days vs an IUCD on lactation. Acta Obstet Gynecol Scand 1997; 76 (Suppl. 167): 53.
22. Godsland IF, Crook D. Pathogenesis of vascular disease in oral contraceptive users. Br J Cardiol 1996; 3: 204–8.
23. Wrinkler UH, Howie H, Buhler K et al. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel. Contraception 1998; 57: 385–92.
24. Carr BR, Ory H. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception 1997; 55: 267–72.
2. Прилепская В.Н. Руководство по контрацепции. М .: МЕДпресс-информ, 2006.
3. Guillebaud J. Contraception. Your questions answered. 2nd edn. Edinburgh: Churchill Livingstone, 1993.
4. WHO, Medical eligibility criteria for contraceptive use, 2004.
5. Rosenberg L, Palmer JR, Sands MI et al. Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol 1997; 177: 707–15.
6. http://www.mzsrrf.ru/stat/44.html
7. LaVecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer. An update. Drug Safety 2001; 24: 741–54.
8. Fraser JS. Long-acting hormonal contraception: a comparison of key medical aspect. Oral presentation FIGO, 2006.
9. McCann MF, Potter LS. Progestin-only contraception: a comprehensive review. Contraception 1994; 50 (Suppl. 1): SI–198.
10. Darney PD. The androgenicity of progestins. Am J Med 1995; 98 (Suppl. 1 A): 104–1 OS.
11. Stone SC. Desogestrel. Clin Odstet Gynecol 1995; 38: 821–8.
12. Rice CF, Killick SR, Dieben T et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 Μg daily. Hum Reprod 1999; 14: 982–5.
13. Van Heusden AM, Fauser BJCM. Residual ovarian activity during oral steroid contraception. Hum Reprod Update 2002; 8: 345–58.
14. Schwartz JL, Creinin MD, Pymar HC, Reid L. Predicting risk of ovulation in new start oral contraceptive users. Obstet Gynecol 2002; 99: 177–82.
15. Pierson RA, Archer DA, Moreau M et al. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003; 80: 34–42.
16. Korver T, Klipping C, Heger-Mahn D et al. Maintenance of ovulation inhibition with the 75 mcg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-hour delays in tablet-intake. Contraception 2005; 7: 8–13.
17. Rice CF, Killick SR, Dieben T. The effect of desogestrel 75 μg and levonorgestrel 30 μg on the endometrium and bleeding patterns over one year. Br J Obstet Gynecol 1998; 105 (Suppl. 17): 114.
18. Obruca A, Korver T, Huber J et al. Ovarian function during and after treatment with new progestagen Org 30659. Fertil Steril 2001; 76: 108–15.
19. Collaborative Study Group on the Desogestrel-Containing Progestogen-only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and Safety of two progestagen-only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day. Eur J Contracept Reproduct Health Care 1998; 3: 169–78.
20. Miller A. Dysmenorrhoea. A systematic approach to management. J Ped Obstet Gynecol 1997; 6: 18–22.
21. Bjarnodotter RI, Geirsson RT, Gottfreosdottir H. An open non-randomised comparative study on the effects of desogestrel 0,075 mg/days vs an IUCD on lactation. Acta Obstet Gynecol Scand 1997; 76 (Suppl. 167): 53.
22. Godsland IF, Crook D. Pathogenesis of vascular disease in oral contraceptive users. Br J Cardiol 1996; 3: 204–8.
23. Wrinkler UH, Howie H, Buhler K et al. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel. Contraception 1998; 57: 385–92.
24. Carr BR, Ory H. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception 1997; 55: 267–72.
________________________________________________
2. Прилепская В.Н. Руководство по контрацепции. М .: МЕДпресс-информ, 2006.
3. Guillebaud J. Contraception. Your questions answered. 2nd edn. Edinburgh: Churchill Livingstone, 1993.
4. WHO, Medical eligibility criteria for contraceptive use, 2004.
5. Rosenberg L, Palmer JR, Sands MI et al. Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol 1997; 177: 707–15.
6. http://www.mzsrrf.ru/stat/44.html
7. LaVecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer. An update. Drug Safety 2001; 24: 741–54.
8. Fraser JS. Long-acting hormonal contraception: a comparison of key medical aspect. Oral presentation FIGO, 2006.
9. McCann MF, Potter LS. Progestin-only contraception: a comprehensive review. Contraception 1994; 50 (Suppl. 1): SI–198.
10. Darney PD. The androgenicity of progestins. Am J Med 1995; 98 (Suppl. 1 A): 104–1 OS.
11. Stone SC. Desogestrel. Clin Odstet Gynecol 1995; 38: 821–8.
12. Rice CF, Killick SR, Dieben T et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 Μg daily. Hum Reprod 1999; 14: 982–5.
13. Van Heusden AM, Fauser BJCM. Residual ovarian activity during oral steroid contraception. Hum Reprod Update 2002; 8: 345–58.
14. Schwartz JL, Creinin MD, Pymar HC, Reid L. Predicting risk of ovulation in new start oral contraceptive users. Obstet Gynecol 2002; 99: 177–82.
15. Pierson RA, Archer DA, Moreau M et al. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003; 80: 34–42.
16. Korver T, Klipping C, Heger-Mahn D et al. Maintenance of ovulation inhibition with the 75 mcg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-hour delays in tablet-intake. Contraception 2005; 7: 8–13.
17. Rice CF, Killick SR, Dieben T. The effect of desogestrel 75 μg and levonorgestrel 30 μg on the endometrium and bleeding patterns over one year. Br J Obstet Gynecol 1998; 105 (Suppl. 17): 114.
18. Obruca A, Korver T, Huber J et al. Ovarian function during and after treatment with new progestagen Org 30659. Fertil Steril 2001; 76: 108–15.
19. Collaborative Study Group on the Desogestrel-Containing Progestogen-only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and Safety of two progestagen-only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day. Eur J Contracept Reproduct Health Care 1998; 3: 169–78.
20. Miller A. Dysmenorrhoea. A systematic approach to management. J Ped Obstet Gynecol 1997; 6: 18–22.
21. Bjarnodotter RI, Geirsson RT, Gottfreosdottir H. An open non-randomised comparative study on the effects of desogestrel 0,075 mg/days vs an IUCD on lactation. Acta Obstet Gynecol Scand 1997; 76 (Suppl. 167): 53.
22. Godsland IF, Crook D. Pathogenesis of vascular disease in oral contraceptive users. Br J Cardiol 1996; 3: 204–8.
23. Wrinkler UH, Howie H, Buhler K et al. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel. Contraception 1998; 57: 385–92.
24. Carr BR, Ory H. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception 1997; 55: 267–72.
Авторы
Н.М.Подзолкова, И.В.Кузнецова, Л.В.Сумятина, Е.А.Богинская
Кафедра акушерства и гинекологии РМАПО (зав. каф. – проф., д.м.н. Н.М.Подзолкова)
Кафедра акушерства и гинекологии РМАПО (зав. каф. – проф., д.м.н. Н.М.Подзолкова)
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.